These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 34904810)

  • 21. PARP and PARG inhibitors in cancer treatment.
    Slade D
    Genes Dev; 2020 Mar; 34(5-6):360-394. PubMed ID: 32029455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
    Ma L; Bian X; Lin W
    J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
    Li Y; Liu CF; Rao GW
    Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine.
    Van Den Borg R; Leonetti A; Tiseo M; Giovannetti E; Peters GJ
    Expert Rev Anticancer Ther; 2019 Jun; 19(6):461-471. PubMed ID: 31148500
    [No Abstract]   [Full Text] [Related]  

  • 26. A genetic snapshot of small cell lung cancer.
    Rosell R; Wannesson L
    Cancer Discov; 2012 Sep; 2(9):769-71. PubMed ID: 22969115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting DNA Damage Response Deficiency in Thoracic Cancers.
    Bzura A; Spicer JB; Dulloo S; Yap TA; Fennell DA
    Drugs; 2024 Sep; 84(9):1025-1033. PubMed ID: 39001941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Darinaparsin (ZIO-101) enhances the sensitivity of small-cell lung cancer to PARP inhibitors.
    Cao GZ; Ma LY; Zhang ZH; Wang XL; Hua JH; Zhang JH; Lv Y; Zhang SB; Ou J; Lin WC
    Acta Pharmacol Sin; 2023 Apr; 44(4):841-852. PubMed ID: 36253561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review.
    Mehta P; Bothra SJ
    Adv Genet; 2021; 108():35-80. PubMed ID: 34844716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PARP1 inhibition elicits immune responses against non-small cell lung cancer.
    Juncheng P; Lafarge A; Kroemer G; Castedo M
    Oncoimmunology; 2022; 11(1):2111915. PubMed ID: 35979387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors.
    Yang ZM; Liao XM; Chen Y; Shen YY; Yang XY; Su Y; Sun YM; Gao YL; Ding J; Zhang A; He JX; Miao ZH
    Acta Pharmacol Sin; 2017 Jul; 38(7):1038-1047. PubMed ID: 28414200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
    Li N; Wang Y; Deng W; Lin SH
    Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
    Zheng F; Zhang Y; Chen S; Weng X; Rao Y; Fang H
    Biomed Pharmacother; 2020 Mar; 123():109661. PubMed ID: 31931287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis.
    Bao Z; Cao C; Geng X; Tian B; Wu Y; Zhang C; Chen Z; Li W; Shen H; Ying S
    Oncotarget; 2016 Feb; 7(7):7629-39. PubMed ID: 26399274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The current status of PARP inhibitors in ovarian cancer.
    McLachlan J; George A; Banerjee S
    Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
    Cardnell RJ; Feng Y; Diao L; Fan YH; Masrorpour F; Wang J; Shen Y; Mills GB; Minna JD; Heymach JV; Byers LA
    Clin Cancer Res; 2013 Nov; 19(22):6322-8. PubMed ID: 24077350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induced degradation of lineage-specific oncoproteins drives the therapeutic vulnerability of small cell lung cancer to PARP inhibitors.
    Kim C; Wang XD; Liu Z; Hao J; Wang S; Li P; Zi Z; Ding Q; Jang S; Kim J; Luo Y; Huffman KE; Pal Choudhuri S; Del Rio S; Cai L; Liang H; Drapkin BJ; Minna JD; Yu Y
    Sci Adv; 2024 Jan; 10(3):eadh2579. PubMed ID: 38241363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.
    Virtanen V; Paunu K; Ahlskog JK; Varnai R; Sipeky C; Sundvall M
    Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review.
    Cook SA; Tinker AV
    BioDrugs; 2019 Jun; 33(3):255-273. PubMed ID: 30895466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Poly(Adenosine Diphosphate-Ribose) Polymerase Inhibition as Maintenance Treatment for SCLC: The Search Must Continue.
    Huddar P; Califano R
    J Thorac Oncol; 2021 Aug; 16(8):1236-1238. PubMed ID: 34304849
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.